Precision medicine data and AI platform for oncology and healthcare
Tempus AI is a technology platform for clinicians and researchers analyzing clinical and molecular data.
AI Panel Score
6 AI reviews
Reviewed
Facts checked against tempus.ai
AI Editor ApprovedApproved and published by our AI Editor-in-Chief after full panel analysis.Tempus AI provides testing and data services used by physicians, hospitals, and life sciences companies. A physician or lab submits a tissue or blood sample, and Tempus runs genomic sequencing (DNA and RNA) along with other molecular tests, then returns a structured report that correlates the results with treatment options, clinical trials, and outcomes data drawn from its patient database. The reports are designed to sit inside existing oncology workflows, giving clinicians a reference point when deciding on therapies for cancer patients.
The platform's distinguishing feature is its data library, which combines molecular sequencing data with clinical data abstracted from medical records, pathology reports, and imaging. Tempus uses natural language processing and machine learning models to structure unstructured clinical notes at scale, then applies algorithms across this combined dataset to identify patterns such as therapy response or disease progression. Specific product lines include Tempus xT (tumor sequencing), Tempus xR (RNA sequencing), an oncology decision-support algorithm portfolio, and tools extending into cardiology and other disease areas through partnerships with health systems and pharmaceutical companies for drug development and clinical trial matching.
Professional services reports leverage MSK's OncoKB database and NCCN Guidelines to match patients to potential FDA-approved therapies and clinical trials.
Clinicians can add algorithmic tests such as homologous recombination deficiency (HRD) and immune profile score (IPS) alongside sequencing results for a more complete molecular picture.
The xF+ panel can measure blood-based tumor mutational burden (bTMB) and microsatellite instability (MSI) as predictive biomarkers for immunotherapy response.
xT CDx includes companion diagnostic claims for colorectal cancer patients, helping identify patients who may benefit from specific FDA-approved targeted therapies.
Provides institutional access to millions of de-identified patient records and proprietary technologies to explore data patterns for collaborative precision oncology research.
Provides whole transcriptome RNA sequencing for solid tumors and hematologic malignancies, identifying clinically relevant gene fusions and altered splicing events like MET exon 14 and EGFRvIII.
Enables a streamlined test ordering process for liquid biopsy and other panels via Tempus Hub, paper requisition, or directly through a provider's EHR.
Offers single-cell sequencing, genome-wide liquid biopsy profiling, spatial transcriptomics, methylation analysis, and genotyping for expanded research applications.
A non-invasive, 105-gene liquid biopsy panel that detects genomic alterations circulating in patient blood, including SNVs, indels, copy number changes, and gene rearrangements.
A 523-gene liquid biopsy panel covering SNVs, indels, copy number gains, and gene rearrangements, which Tempus describes as one of the largest liquid biopsy panels available on the global market.
An FDA-approved 648-gene tissue-based next-generation sequencing test for molecular profiling of all malignant solid tumors, using a tumor plus matched normal approach.
Combines genomic, transcriptomic, and clinical data into an integrated multi-omic analytical platform to support research and treatment decisions.
Tempus AI does not publish public list pricing. Their genomic sequencing tests (e.g., Tempus xT, xF, xE), AI-enabled diagnostics, and data/software platform are billed via insurance reimbursement, health system contracts, and enterprise data licensing agreements negotiated directly with the company. Prospective customers (clinicians, health systems, biopharma partners) must contact Tempus AI's sales team for a quote.
Public company, FDA-cleared tests, real revenue — this isn't a science project.
“Tempus AI is a public, revenue-generating precision oncology platform with FDA-approved diagnostics. The gap is pricing transparency — there's none.”
Tempus AI trades on Nasdaq. That alone separates it from ninety percent of AI-healthcare pitches — this vendor has audited financials, not a Series A deck.
The xT CDx is FDA-approved, a 648-gene tissue test, and the xF+ liquid biopsy panel covers 523 genes — they call it one of the largest on the market. That's not vaporware; that's a lab with regulatory clearance competing against Foundation Medicine and Guardant Health.
Two concerns. No pricing page, no published plans — everything's "contact us," which means procurement will take months, not weeks. Second: this is a diagnostics and data vendor, not a workflow tool your IT team controls — integration depends on their EHR partnerships, not yours. Fine for a health system. Overkill and slow for anyone without an oncology practice.
Competes directly with Foundation Medicine and Guardant Health in a market where peers already use genomic testing vendors.
FDA approval of xT CDx and use of MSK's OncoKB and NCCN Guidelines signal clinical credibility to a board.
No pricing page or self-serve trial; contact-only sales cycle slows time to first report.
Advances precision oncology capability rather than just cutting cost on existing genomic testing spend.
Public company (Nasdaq) with FDA-approved products — far past the startup-mortality risk zone.
Health systems and pharma companies needing FDA-approved genomic testing tied to real-world outcomes data.
Skip if you need fast procurement or a workflow tool outside oncology.
Strong molecular diagnostics backbone for oncology, but the clinical decision layer still needs a tumor board's judgment.
“Tempus xT CDx and the 523-gene xF+ panel are genuinely differentiated assets in the tumor sequencing landscape. The gap is transparency around how the AI-derived treatment insights get validated at the bedside.”
As a CMO evaluating molecular platforms, I care about two things: analytic validity and how the output changes my tumor boards' behavior. xT CDx is FDA-approved for 648 genes, and xF+ covers 523 genes, which Tempus calls one of the largest liquid biopsy panels available. That's real depth, comparable to Foundation Medicine's FoundationOneCDx, and the OncoKB/NCCN-anchored trial matching gives oncologists a defensible reference point.
My hesitation is the decision-support layer sitting on top of the sequencing. NLP-structured real-world data across millions of patients is a genuine research asset, but the site gives no pricing model, no outcomes validation detail, and no clarity on algorithm performance monitoring.
Over three years, adopting Tempus embeds you in their data ecosystem and EHR ordering workflow (Tempus Hub), which is sticky but also a lock-in. Fine for large academic centers; risky for smaller systems without informatics staff to audit model drift.
Sits alongside Foundation Medicine and Guardant Health as a top-tier precision oncology data company.
Reports are built to sit inside oncology workflows and EHR ordering via Tempus Hub, matching how tumor boards actually operate.
EHR and paper requisition ordering paths exist, but without a public API or integration docs, deeper systems integration is hard to assess.
Data-library lock-in and unclear algorithm validation cadence create a 3-year dependency question for health systems.
648-gene xT CDx and 523-gene xF+ panels represent genuine sequencing depth, not a thin wrapper product.
Academic cancer centers and health systems with informatics capacity to vet AI-driven treatment insights.
You're a smaller oncology practice without the staff to audit molecular algorithm performance over time.
No pricing page. No tiers. Just 'contact us' and a 648-gene test.
“Zero published pricing on a clinical diagnostic product. This is a per-test, per-contract, insurance-and-institution billing model — not SaaS math.”
No pricing plans found. Not a gap, a category norm — diagnostics bill payers and institutions, not seats. xT CDx is a 648-gene tissue test. xF+ is a 523-gene liquid biopsy panel. None have public prices. Compare to Foundation Medicine, which also negotiates per-payer, per-contract. Category norm, but it kills quick TCO math.
Real cost driver isn't the sequencing fee. It's integration: EHR ordering via Tempus Hub, institutional data access agreements, reimbursement cycles with payers. Three-year TCO depends on test volume and payer mix, not a rate card. Finance can't model this without a signed contract in hand.
ROI is measurable at the patient level — did the therapy match work — but the billing model means procurement negotiates institution-by-institution. No self-serve tier. No visible term length. No auto-renewal disclosure. Budget owners should expect a multi-month contracting cycle before the first invoice arrives.
Ordering runs through Tempus Hub or EHR integration, but payer billing and institutional onboarding add real friction.
No published term length or auto-renewal terms; institutional healthcare contracts are typically multi-year and rigid.
No pricing plans, no tiers, no rate card — pure contact-sales model.
Therapy-matching outcomes via OncoKB and NCCN Guidelines are trackable per patient, but no aggregate ROI benchmark published.
Per-test billing plus EHR integration via Tempus Hub means costs scale with volume, unmodelable without a contract.
Health systems and pharma partners with dedicated procurement teams for multi-year diagnostic contracts.
You need transparent, comparable pricing before committing budget.
Deep molecular data, but the report still lands as a PDF-shaped decision aid, not a workflow
“xT CDx and xF+ give oncologists FDA-approved, guideline-linked biomarker answers that are genuinely useful at the tumor board. Getting that data to talk to the EMR, and to the rest of my week, is a separate problem Tempus doesn't fully own.”
xT CDx (648-gene tissue panel) and xF+ (523-gene liquid biopsy, one of the largest available, per Tempus) generate real signal — HRD, IPS, bTMB, MSI-H all layered onto one report tied to OncoKB and NCCN Guidelines. That's a genuinely strong reference point mid-tumor-board.
Day-3 reality: ordering through Tempus Hub, paper requisition, or EHR integration are three different paths depending on your health system's setup, and which one you get isn't always your choice. Turnaround, at least, is published — Tempus's clinic ordering guide lists about 9 days after specimen receipt for xT and xR, and 7-9 days for xF. The ordering path is the gap versus Foundation Medicine, where ordering friction is at least a known quantity.
No public pricing, no free trial — every deal goes through a rep, which is normal for this category but means no self-serve evaluation before committing a patient sample.
Report quality (OncoKB/NCCN-linked) holds up past the pitch, and Tempus publishes turnaround per test (about 9 days for xT and xR, 7-9 for xF), though the ordering path still varies by health system.
Tempus publishes a clinic ordering guide with turnaround, specimen type and collection kit per test, but I couldn't find an API or developer docs for health-system IT.
No pricing page, no self-serve trial — every friction point routes through a sales conversation.
Single-cell sequencing, spatial transcriptomics, methylation analysis and multi-omic integration give real depth for research-heavy users.
Three separate ordering paths (Hub, paper requisition, EHR) suggest integration depth varies a lot by health system.
Oncology practices and health systems that need deep genomic-plus-clinical data and can absorb a sales-driven onboarding process.
You need transparent pricing or self-serve evaluation before looping in procurement.
Serious lab science, but the ordering-desk experience is a black box from the outside.
“Tempus has the genomic firepower — 648-gene xT CDx, a 523-gene liquid biopsy panel — but there's little visible product polish to judge. No pricing page, no API reference I could find, no way to see what a physician's day actually looks like.”
The science stack is real. xT CDx is FDA-approved, 648 genes, tumor-plus-matched-normal. xF+ is a 523-gene liquid biopsy panel that Tempus calls one of the largest on the market. That's not marketing fluff, that's a specific number you can check against competitors like Foundation Medicine and Guardant Health.
But as a product, I've got little to go on beyond the test documentation: technical information, validation summaries, specimen and requisition guides. No pricing page, and I couldn't find an API reference or a changelog. 'Contact us' pricing is normal for this category, but it also means every buyer starts from zero information, which is homework before you've even signed anything.
Tempus Hub is the ordering layer — EHR integration, paper requisition, the works — and that's the actual daily-use surface for clinicians. The Tempus Provider app for iPhone, iPad and Android puts reports, patient search and order tracking on a phone, but whether Hub feels solid or clunky day to day isn't something I can judge from outside. That's the tradeoff: deep science, thin visible UX.
Tempus Hub is where daily polish would live; its mobile app lists reports, patient search and order tracking, but I couldn't judge the feel from outside.
Reports designed to sit inside existing oncology workflows, easing adoption, but multi-omic tools like xR and single-cell sequencing add real depth to master over time.
Tempus Provider app on iPhone, iPad and Android gives oncologists reports, patient search and order tracking; I couldn't find in-app test ordering.
No pricing page or self-serve trial — beyond the published test documentation, a buyer goes through sales contact before seeing the product.
FDA-approved xT CDx and companion diagnostic claims suggest regulated, validated processes even if UI reliability is unknown.
Hospital systems and oncology practices ready to commit to a full genomic testing and data partnership.
You need transparent self-serve pricing or a quick trial before looping in procurement.
Public company, FDA-approved test, no pricing page. That's the split.
“Tempus is a real, revenue-generating diagnostics company, not a vaporware AI wrapper. But 'contact us' pricing and zero API docs make it hard to evaluate like a normal SaaS buy.”
This one's different from the usual AI-healthcare pitch. xT CDx is FDA-approved, 648 genes, tumor plus matched normal. xF+ is a 523-gene liquid biopsy panel that Tempus calls one of the largest available. Those are checkable claims, not vibes. Foundation Medicine and Guardant Health are the obvious comparisons here, and Tempus competing on panel size against both is a real differentiation argument, not marketing fluff.
What's missing: no pricing page, and I couldn't find an API or a changelog; the documentation that exists is test-level (technical information, validation summaries, specimen guides). For a diagnostics company selling into hospital procurement that's normal — category norm is enterprise sales cycles, not self-serve. But it means due diligence happens off-platform, through sales calls, which cuts against transparency.
Exit portability is the real question. Once a health system's workflow depends on Tempus Hub for ordering and its data library for insights, switching to Foundation Medicine or Guardant means re-validating clinical pathways, not just swapping vendors.
Competes on panel size (523 genes) against Foundation Medicine and Guardant Health, a real but narrow edge.
Clinical workflow lock-in via Tempus Hub and proprietary data library makes switching costly, no migration story given.
Public company status and named product lines (xT, xR, xF+) suggest durability, though I couldn't find a public product roadmap.
Claims like a 523-gene liquid biopsy panel and a 648-gene FDA-approved tissue test are specific and checkable, not vague superlatives.
FDA-approved xT CDx and public company status match successful diagnostics patterns, unlike unproven AI-only entrants.
Hospitals and life sciences companies needing FDA-approved genomic profiling integrated into oncology workflows.
You need transparent self-serve pricing or plan to evaluate without a sales cycle.
Common questions answered by our AI research team
Tempus AI sequences tumor and molecular data and connects it with clinical records to support physician decision-making.
It uses a real-world data library built from de-identified clinical and molecular records to train algorithms that detect patterns relevant to diagnosis and treatment selection.
Tempus AI primarily focuses on oncology.
Yes, the clinical and molecular records in Tempus AI's data library are de-identified.
Who Tempus AI competes with, and how each one differs
Named in the Tempus FY2025 Form 10-K as a primary competitor for its marketed precision oncology tests. Caris (Nasdaq: CAI, Irving, Texas) runs its own tissue and liquid molecular profiling labs and licenses AI-derived molecular datasets to pharma, the closest structural match to the Tempus diagnostics-plus-data model; it listed on Nasdaq in June 2025, a year after Tempus.
Named in the Tempus FY2025 Form 10-K as a main competitor for the Data and applications product line. Flatiron, a Roche subsidiary, assembles oncology real-world datasets from its own OncoEMR practice software and sells them to life-sciences customers, whereas Tempus generates its data as a byproduct of running the sequencing lab itself.
Competes head-on with Paige, the digital-pathology company Tempus acquired in August 2025 for $101.5 million. PathAI sells AI pathology algorithms and its AISight image-management platform to pharma and laboratories as software, while Tempus embeds pathology models in a lab it operates and bills through diagnostics.
Sells its SOPHiA DDM genomic-analysis platform as software to hospitals and laboratories that run their own sequencers, a decentralized model. Tempus centralizes sequencing in its own CLIA labs and monetizes the resulting multimodal dataset through pharma data licensing, so the two compete for genomic interpretation budgets from opposite directions.
Overlaps the Tempus Data and applications business in selling real-world evidence to life-sciences companies, but the Komodo Healthcare Map is built from de-identified claims and encounter data across all disease areas rather than from clinical-genomic records generated in an oncology laboratory.
Tempus AI is a Chicago-based healthcare technology company that uses artificial intelligence and molecular data to support precision medicine and drug development.
